Tempus AI
Tempus AI is a precision-medicine company that applies machine learning to clinical and molecular data, principally in oncology, to support diagnostics and treatment selection. It operates sequencing laboratories and maintains a large library of de-identified clinical and genomic data, and listed on the Nasdaq in June 2024.
- Founded
- 2015
- Headquarters
- Chicago, Illinois, US
- Founders
- Eric Lefkofsky
- Status
- Public (Nasdaq: TEM)
- Total funding
- ~$1.42B (pre-IPO)
- Latest round
- IPO (June 2024)
- Valuation
- ~$6.1B at IPO (June 2024)
- Key investors
- Baillie Gifford, New Enterprise Associates, Novo Holdings, T. Rowe Price, Google, SoftBank Group
- Employees
- ~3,000
- Category
- AI diagnostics & precision medicine
- Products
- Tempus One, xT / xF / xR sequencing assays, Tempus data library
- Website
- www.tempus.com
Covered in: Artificial Intelligence in Healthcare, Health Data and Analytics
Profile compiled from the public sources listed above. Funding, valuation, and employee figures are point-in-time and may be out of date.